(Q88890554)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

title

Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Antonio González Martín

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

publication date

29 November 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

28 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

8-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

Hereditary breast and ovarian cancer: new genes in confined pathways

28 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930621-0

7 January 2021

10.1016/S1470-2045(16)30621-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27908593%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference